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The vitamin D receptor (VDR) is a nuclear, ligand-dependent transcription factor that in com-
plex with hormonally active vitamin D, 1,25(OH)2D3, regulates the expression of more than
900 genes involved in a wide array of physiological functions. The impact of 1,25(OH)2D3-
VDR signaling on immune function has been the focus of many recent studies as a link
between 1,25(OH)2D3 and susceptibility to various infections and to development of a
variety of inflammatory diseases has been suggested. It is also becoming increasingly
clear that microbes slow down immune reactivity by dysregulating the VDR ultimately to
increase their chance of survival. Immune modulatory therapies that enhance VDR expres-
sion and activity are therefore considered in the clinic today to a greater extent. As T cells
are of great importance for both protective immunity and development of inflammatory dis-
eases a variety of studies have been engaged investigating the impact of VDR expression
in T cells and found that VDR expression and activity plays an important role in both T cell
development, differentiation and effector function. In this review we will analyze current
knowledge of VDR regulation and function inT cells and discuss its importance for immune
activity.
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INTRODUCTION
The purpose of the immune system is to recognize and clear
pathogens from the body. However, occasionally unwanted
immune reactions against self-tissue that lead to autoimmune
diseases occur. The frequency of autoimmune diseases such
as type 1 diabetes mellitus (Staples et al., 2003; Sloka et al.,
2010), rheumatoid arthritis (Vieira et al., 2010), multiple scle-
rosis (MS) (Hogancamp et al., 1997), and inflammatory bowel
disease (Khalili et al., 2012) has been linked to geographic loca-
tion with a higher incidence of these diseases at higher degrees
of latitude. One explanation of this geographical distribution is
low exposure to sunlight and hence lower levels of vitamin D
(25(OH)D3) at higher degrees of latitude, as confirmed by studies
showing an association between low serum levels of 25(OH)D3
and development of autoimmune diseases (Pierrot-Deseilligny
and Souberbielle, 2010; Rossini et al., 2010; Greer et al., 2012).
Low serum levels of 25(OH)D3 have also been linked to higher
susceptibility to infections such as tuberculosis (Nnoaham and
Clarke, 2008), influenza (Cannell et al., 2006; Grant, 2008), HIV
(Rodriguez et al., 2009), respiratory syncytial virus (Grant, 2008),
and viral infections of the upper respiratory tract (Ginde et al.,
2009). It is therefore apparent that vitamin D plays a role in
immune modulation. A recent acknowledgment that the major-
ity of immune cells expresses the vitamin D receptor (VDR)
(Kreutz et al., 1993; Hewison et al., 2003; Baeke et al., 2010; von
Essen et al., 2010; Geldmeyer-Hilt et al., 2011; Joseph et al., 2012)
and also the enzyme CYP27B1 used for internal conversion of
circulating 25(OH)D3 to the VDR-ligand 1,25(OH)2D3 (Hewi-
son et al., 2003; Baeke et al., 2010) has further strengthen this
perception.
VITAMIN D, VDR, AND T CELL FUNCTION
MECHANISM OF 1,25(OH)2D3 ACTION
The cellular actions of 1,25(OH)2D3 are mediated by the VDR,
a ligand-dependent transcription regulator molecule belong-
ing to the superfamily of nuclear receptors. In the absence of
1,25(OH)2D3-VDR is mainly distributed to the cytoplasm (Nag-
pal et al., 2005). Interaction of VDR with its ligand 1,25(OH)2D3
induces formation of two independent protein interaction sur-
faces on the VDR, one that facilitates association with the
retinoid X receptor (RXR) necessary for DNA binding, and one
that is required for recruitment of co-regulators necessary for
gene modulation (Pike et al., 2012). Following interaction with
1,25(OH)2D3-VDR dimerizes with RXR and translocates to the
nucleus where it binds to vitamin D response elements (VDRE) in
vitamin D responsive genes. Depending on the target gene either
co-activators or co-repressors are attracted to the VDR/RXR com-
plexes to induce or repress gene transcription (Nagpal et al., 2005;
Pike et al., 2012; Haussler et al., 2013). Even though details of how
these co-regulatory complexes work are only slowly beginning to
emerge, it is now evident that they include ATPase-containing
nucleosomal remodeling capabilities, enzymes with chromatin
histone modifying abilities (e.g., acetyl- or methyl-transferases)
and proteins involved in recruitment of RNA polymerase II (Pike
et al., 2012; Haussler et al., 2013). Besides regulation through
VDRE, VDR can inhibit genes by antagonizing certain transcrip-
tion factors (Alroy et al., 1995; Takeuchi et al., 1998; Towers and
Freedman, 1998). One such example is VDR-dependent inhibi-
tion of the T cell cytokine IL-2. Here, VDR first competes with the
transcription factor NFAT1 for binding to the enhancer motif of
AP1 and subsequently VDR binds to c-Jun. This co-occupancy of
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VDR-c-Jun to AP1 leads to inhibition of IL-2 expression. The VDR
inhibition of the IL-2 gene requires that VDR dimerizes with RXR,
illustrating a need for 1,25(OH)2D3 (Alroy et al., 1995; Takeuchi
et al., 1998; Towers and Freedman, 1998). Overall, the cellular
action of vitamin D therefore depends on sufficient production
and delivery of 1,25(OH)2D3 and adequate expression of VDR
and its associated proteins. Since the VDR in 1983 was reported
to be expressed in immune cells (Bhalla et al., 1983; Provvedini
et al., 1983) an increasing effort to elucidate the importance of vit-
amin D on immune function has been undertaken. It has become
increasingly clear that a major mechanism to control the immune
regulatory effect of vitamin D is adjustment of the expression level
and activity of the VDR.
VDR EXPRESSION AND DEVELOPMENT OF T CELLS
Due to the importance of T cells in protective immunity and in
development of inflammatory and autoimmune disorders, sev-
eral studies have examined the impact of VDR expression on T
cell development, differentiation, and function. One approach to
determine the role of VDR expression in development of T cells
has been to study mice lacking the VDR (VDR-KO). These mice
show normal numbers of CD4+ and CD8+ T cells including natu-
rally occurring CD4+ FoxP3+ regulatory T cells (nTreg) (Yu et al.,
2008), suggesting that VDR is not required for development of
either of these cell types. A study performed by Hayes and cowork-
ers using a mouse model with defective VDR in only the T cells
confirmed that VDR is not essential for development of either con-
ventional CD4+ T cells, CD8+ T cells, or CD4+ FoxP3+ nTreg cells
(Mayne et al., 2011). Even so,VDR-KO mice appear to have a more
vigorous immune response as seen by their increased risk of devel-
opment of autoimmune diseases (Froicu et al., 2003; Froicu and
Cantorna, 2007), and the enhanced response of VDR-KO T cells
in mixed lymphocyte reactions (Froicu et al., 2003). In a series of
studies Cantorna and coworkers have establish that the increased
immune reactivity observed in VDR-KO mice in part is caused
by a failure to develop the two regulatory T cell subsets, invariant
NKT (iNKT) cells and CD8αα/TCRαβ T cells (Yu and Cantorna,
2008; Yu et al., 2008; Bruce and Cantorna, 2011). iNKT cells are
a subset of T cells with a regulatory role in autoimmunity and
infection (Godfrey et al., 2000; Bendelac et al., 2001; Singh et al.,
2001). CD8ααT cells are mainly present in the gut, where they help
maintain tolerance and suppress inflammation by dampening the
response to a large number of gut antigens (Poussier et al., 2002;
Cheroutre, 2004). The VDR-KO mice have significant fewer iNKT
cells, due to a block in development as VDR is implicated in Tbet
expression and conversion to the mature NK1.1 expressing mature
iNKT cell. The few iNKT cells present in the periphery are further-
more functionally defective (Yu and Cantorna, 2008; Ooi et al.,
2012). Like the iNKT cells, there are also fewer CD8αα/TCRαβpre-
cursors in the thymus of VDR-KO animals. Moreover, to complete
development CD8αα/TCRαβ cells must travel from the thymus
to the gastrointestinal tract where IL-15 induces proliferation and
upregulation of CD8αα. Due to decreased levels of IL-15 recep-
tor expression VDR-KO CD8αα/TCRαβ cells proliferate poorly,
resulting in a diminished mature CD8αα/TCRαβ population in
the VDR-KO gut (Yu et al., 2008; Bruce and Cantorna, 2011; Ooi
et al., 2012). These data illustrate that in contrast to conventional
T cells, VDR expression is mandatory for development of both
iNKT cells and CD8αα/TCRαβ T cells.
VDR EXPRESSION AND DIFFERENTIATION OF T CELLS
Adaptive immune responses require priming and proliferation of
naïve T cells followed by migration of the resulting effector T
cells to the site of infection. Antigen-specific triggering of TCRs
expressed on the surface of antigen-naïve T cells together with
co-stimulation induces intracellular signaling events that pro-
mote upregulation of the VDR (Provvedini et al., 1983; von Essen
et al., 2010; Joseph et al., 2012). This activation-induced upregu-
lation of VDR in naïve human T cells encourages 1,25(OH)2D3-
VDR signaling. 1,25(OH)2D3-VDR signaling induces upregula-
tion of the VDRE containing enzyme PLC-γ1, which is a cen-
tral molecule in the classical TCR signaling pathway. Following
VDR-induced PLC-γ1 upregulation classical TCR signaling is
established and full T cell activation accomplished (von Essen
et al., 2010). VDR expression therefore contributes to priming
of naïve human T cells. Interestingly, this VDR-induced PLC-
γ1 upregulation is not a mechanism involved in T cell priming
of mouse T cells, as naïve mouse T cells already expresses sub-
stantial amounts of PLC-γ1 (Ericsson et al., 1996). In order for
T cells to proliferate they need the cytokine IL-2. IL-2 is pro-
duced and secreted by T cells in response to antigen-induced T
cell stimulation. In an autocrine and paracrine fashion IL-2 binds
to high affinity IL-2 receptors on the same or adjacent T cells,
inducing cell proliferation and hence a clonally expanded pop-
ulation of antigen-specific effector T cells (Cantrell and Smith,
1984; Smith, 1988). As VDR expression has been shown to inhibit
transcription of the IL-2 gene (Alroy et al., 1995; Takeuchi et al.,
1998), it is likely that upregulation of VDR serves as a nega-
tive feedback mechanism to control potential overreactions of
the immune system. Besides inducing the early priming phase
of naïve human T cells and possibly ensuring immune integrity,
Mathieu and coworkers showed that a 1,25(OH)2D3 agonist dras-
tically changed the surface expression of homing receptors on
both CD4 and CD8 T cells, resulting in a profile corresponding
to an increased migration ability to sites of infection (Baeke et al.,
2011); and hence implying a role for VDR in all phases of T cell
differentiation.
In agreement with a suggested role of VDR in prevent-
ing immune overreaction, a changed distribution of naïve and
antigen-experienced T cells was observed in a VDR-KO study per-
formed by Bruce et al. (2011). The CD4+ T cells had a more
activated phenotype and readily developed into the proinflam-
matory Th17 effector cells that produced twice as much IL-17 as
their WT counterparts in vitro (Bruce et al., 2011). Furthermore,
vitamin D has been shown to modify the phenotype of antigen
presenting dendritic cells (DC) to a more tolerogenic phenotype
that favors differentiation of inducible Treg (iTreg) cells instead of
the inflammatory Th1 and Th17 cells (Griffin et al., 2001; Adorini
et al., 2003; Adorini and Penna, 2009). In VDR-KO mice, the fre-
quency of total DC populations were not affected, but a significant
reduction in tolerogenic DCs was observed (Bruce et al., 2011). In
accordance with the reduced population of tolerogenic DCs and
increased population of activated inflammatory T cells, a decrease
in the population of iTregs that differentiated from naïve T cells
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was observed (Bruce et al., 2011). This lead to an increased path-
ogenic potential of the T cell population, which manifested in
development of more severe experimental inflammatory bowel
disease (Bruce et al., 2011). These observations emphasize the
importance of VDR expression in controlling the balance between
effector and tolerogenic cells.
VDR EXPRESSION AND FUNCTION OF T CELLS
Only few studies have investigated whether there is coherence
between VDR expression and T cell effector function. In the iNKT
cell study performed by Cantorna and coworkers, a reduction
of at least fifty percent in iNKT cells that produced the effector
cytokine IL-4 and IFN-γ was observed in multiple organs (Yu
and Cantorna, 2008). However, as iNKT cells most likely acquire
the ability to transcribe IL-4 and IFN-γ during thymic develop-
ment at the stage where they diverge from conventional T cells
(Bezbradica et al., 2006), it is possible that the reduced cytokine
production observed is due to defects in iNKT cell development.
In a study of conventional T cells from VDR-KO mice, Bruce et al.
(2011) showed that VDR-KO Th17 cells induced in in vitro cul-
tures overproduced IL-17 as compared to WT cells. In contrast
to the study performed by Cantorna using iNKT cells from VDR-
KO mice, Bruce et al. found no change in IFN-γ production in
the cultured conventional VDR-KO T cells. Taking this into con-
sideration and the fact that Th17 cells are more readily induced
in the VDR-KO mice, it is likely that the increased IL-17 pro-
duction observed by Bruce et al. (2011) is also a developmental
defect. Conversely, an in vitro study in human T cells performed
by Youssef and coworkers favors a direct effect of VDR on IL-
17 production. Here they showed that VDR blocks binding of
the transcription factor NFAT1 to the promoter of the human
IL-17 gene leading to a decrease in IL-17 production (Joshi et al.,
2011). This inhibitory mechanism somehow resemblesVDR’s con-
trol of both IL-2 and GM-CSF transcription in which VDR also
inhibits NFAT1 binding to the DNA of the respective cytokine
genes (Figure 1) (Alroy et al., 1995; Takeuchi et al., 1998; Towers
and Freedman, 1998). As NFAT1 is a transcription factor involved
in regulation of a wide range of genes and as VDR’s inhibition
of NFAT1 appears not to include a canonical VDRE sequence in
the promoter regions (Towers and Freedman, 1998), the transcrip-
tional control of VDR’s target genes is likely far more widespread
than first anticipated. Today, a direct effect of 1,25(OH)2D3-VDR
signaling on the expression of effector T cell molecules includes
not only cytokines but also chemokines and chemokine homing
receptors as reviewed by Peelen et al. (2011).
Studies in which either T cell conditional VDR knock-out ani-
mals or animal models of adoptive transferred T cells from a VDR
knock-out animal would substantially increase our understanding
of VDR’s direct influence on T cell effector function. Along this
line Hayes and coworkers developed a mouse model in which only
the T cells included an inactive VDR gene in order to investigate
the implication of T cells in development of autoimmunity. In this
model T cells developed normally in thymus but peripheral T cells
expressing an inactive VDR were resistant to the inhibitory effect
of vitamin D on autoimmune disease development (Mayne et al.,
2011). Future studies will likely elaborate on specific T cell effector
functions in similar animal models.
ALLELIC VARIATIONS AND NON-FUNCTIONAL VDR IN THE HUMAN
POPULATION
Allelic variants of the VDR gene occur naturally in the human pop-
ulation. Even though interpretation of these polymorphic variants
in relation to different diseases is difficult due to the small numbers
of subjects included in the performed studies, an association with
disease risk has been suggested. This includes a greater suscepti-
bility to infections and a higher incidence of autoimmune diseases
and cancer. The impact of VDR polymorphism on VDR function
may in part be due to reduced VDR-mRNA stability and hence
of reduced VDR expression (Feldman et al., 2005). In addition to
allelic variations of the VDR gene, a rare genetic disorder has been
described in which the VDR gene contain mutations that renders
the gene product non-functional. This includes mutations in the
DNA-binding domain and in the ligand binding domain, render-
ing binding of VDR to DNA, RXR, or co-regulators impossible
(Malloy and Feldman, 2010). Individuals with a non-functional
VDR suffer from the absence of VDR signaling giving rise to
the disease hereditary vitamin D resistant rickets (HVDRR). In
HVDRR patients the serum level of 1,25(OH)2D3 is exceedingly
high and most patients are completely resistant to vitamin D ther-
apy. As there are only very few cases of HVDRR, long-term effects
of defective VDR signaling on immune function such as devel-
opment of autoimmune diseases and control of cancer have not
yet been documented (Malloy and Feldman, 2010). A promising
model system regarding this issue is the VDR-KO mouse in which
the VDR gene has been deleted. These mice show increased sensi-
tivity to autoimmune diseases, and are more prone to oncogene-
and chemocarcinogen-induced tumors (Bouillon et al., 2008)
illustrating a possible in vivo relation between VDR expression
and immune function.
REGULATION OF VDR EXPRESSION AND ACTIVITY
The studies described above have led to an understanding of the
importance of VDR expression in T cell development, differen-
tiation, and function. Even though the abundance of VDR in T
cells reflects the cells responsiveness to 1,25(OH)2D3, this concept
likely is far more complex. Besides transcriptional regulation of the
VDR, additional factors with an impact on VDR activity should be
considered. This includes ligand availability, induction of intracel-
lular signaling pathways, posttranslational modifications of VDR,
nuclear translocation, and DNA binding as well as recruitment of
activated co-regulators.
LIGAND AVAILABILITY
The role of the VDR-ligand 1,25(OH)2D3 is to convert VDR into
a functionally active protein that can bind to RXR and to spe-
cific gene sequences and co-regulators necessary for modulation
of gene expression (Pike, 2011; Pike et al., 2012; Haussler et al.,
2013). Availability of 1,25(OH)2D3 is therefore a prerequisite for
VDR activity. The circulating concentration of 1,25(OH)2D3 is
very low (≤100 pM) compared to its metabolic inactive precur-
sor 25(OH)D3 (≤100 nM) (Feldman et al., 2005). During an
immune reaction it is therefore most likely that the source of
1,25(OH)2D3 predominantly is endogenous production from the
precursor molecule 25(OH)D3. In support of this, several studies
of immune cells have revealed that 25(OH)D3 can be taken up and
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FIGURE 1 | Proposed model forVDR signaling inT cells. Various
extracellular signals including infection, inflammation, steroid and peptide
hormones, and diet are involved in regulation of the intracellular VDR level.
During an immune response the TCR is triggered by specific antigens,
inducing a cascade of intracellular signaling events. Among these, lck and
ZAP-70 are activated leading to activation of the p38 kinase which in naïve
human T cells induce expression of VDR. TCR triggering also promotes
expression of the 1,25(OH)2D3 synthesis enzyme CYP27B1. Through intrinsic
synthesis of 1,25(OH)2D3 and uptake of 1,25(OH)2D3 from the extracellular
environment, VDR is activated and translocated into the nucleus where it
either induce or suppress transcription of a variety of genes. As an example,
VDR induce upregulation of PLC-γ1 in naïve human T cells. Once PLC-γ1 is
expressed, TCR induced activation of PLC-γ1 leads to activation of PKA and
PKC and an increase in the intracellular calcium level. In other cell types PKA
and PKC has been shown to modulate expression of VDR, depending on the
particular cell type and cellular differentiation state investigated. An increase in
intracellular calcium concentration activates NFAT1 a necessary transcription
factor for expression of IL-2 and other cytokines. IL-2 is a cytokine required for
proliferation of T cells and one mechanism by which VDR adjust T cell activity
is to outcompete NFAT1’s binding to the IL-2 promoter and furthermore to
down-regulate the actual expression of NFAT1. To control VDR activity a series
of negative feedback loops exists; activated VDR both induce expression of
the 1,25(OH)2D3 degrading enzyme CYP24A1 and down-regulates expression
of the 1,25(OH)2D3 synthesizing enzyme CYP27B1.
subsequently converted into 1,25(OH)2D3 through the action of
the enzyme CYP27B1 (Figure 1) (Jeffery et al., 2012). CYP27B1
has been identified in most cells of the immune system (Fritsche
et al., 2003; Liu et al., 2006; Sigmundsdottir et al., 2007; Krutzik
et al., 2008; Correale et al., 2009; Baeke et al., 2010), however, it
is not clear whether all cells can take up the precursor 25(OH)D3
and convert it. When 1,25(OH)2D3 is synthesized a great part is
secreted to adjacent cells, minimizing the need for endogenous
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production in all immune cells (Jeffery et al., 2012). In addition,
1,25(OH)2D3 holds the capacity to restrict its own synthesis by
exerting a negative feedback on the vitamin D signaling system.
1,25(OH)2D3 induces displacement of a key transcriptional fac-
tor responsible for CYP27B1 expression leading to a decrease in
CYP27B1 (Murayama et al., 1999) and also induces a rapid bind-
ing of VDR-RXR to the promoter sequence of the 1,25(OH)2D3
degrading enzyme CYP24A1 leading to an increase in CYP24A1
(Figure 1) (Ohyama et al., 1996; Kim et al., 2005). The net result is
a reduction in endogenous 1,25(OH)2D3. As illustrated by Vidal
et al. this negative feedback mechanism can be partly prevented
by inflammatory-induced proteins. In this study, they showed that
IFN-γ induced activation of STAT1 promoted binding of STAT1 to
the DNA-binding domain of VDR, preventing VDR from inducing
expression of CYP24A1 (Vidal et al., 2002).
A major determinant of 25(OH)D3 availability is the carrier
protein DBP that binds most circulating vitamin D in the serum.
In immune reactions DBP restricts the availability of 25(OH)D3
to the immune cells (Chun et al., 2010; Jeffery et al., 2012). More
than 100 genotypes of DBP have been documented but most
people express the three most common variants GC1S, GC1F,
and GC2 (Arnaud and Constans, 1993). These DBP variants
have different properties including a difference in their affinity
for 25(OH)D3 (Arnaud and Constans, 1993; Wood et al., 2011).
In vitro studies performed with immune cells using different DBP
genotypes in addition to 25(OH)D3 have shown that the par-
ticular genotype used influences the magnitude of the immune
response (Chun et al., 2010; Jeffery et al., 2012). Along this
line, an association between DBP genotype and development of
inflammatory diseases has been described (Papiha and Pal, 1985;
Speeckaert et al., 2006; Martineau et al., 2010). 1,25(OH)2D3
availability therefore is the sum of the circulating 25(OH)D3
level, DBP genotype, CYP27B1 function, near proximity to other
cells that produces and secretes 1,25(OH)2D3 and 1,25(OH)2D3
self-restriction.
EXTRACELLULAR SIGNALS THAT MODULATE VDR EXPRESSION
Vitamin D receptor expression can be modulated by numer-
ous physical stimuli such as dietary composition (e.g., calcium
and phosphorus), steroid hormones, growth factors, peptide hor-
mones (Feldman et al., 2011), and inflammatory agents (Provve-
dini et al., 1983; Liu et al., 2006, 2009; von Essen et al., 2010; Joseph
et al., 2012). For example,VDR expression is significantly regulated
by the steroid hormones estrogen, glucocorticoid, and retinoids
which appears to be rather cell specific (Feldman et al., 2011).
The effect of glucocorticoid on VDR expression in the immune
system has not been evaluated, but glucocorticoids are known
to have a profound anti-inflammatory and immune suppressive
effect (Miller and Ranatunga, 2012). Glucocorticoid therapy is
used to suppress inflammation implicated in the pathogenesis of
various inflammatory diseases (Hanaoka et al., 2012; Miller and
Ranatunga, 2012), and it could be speculated that one mecha-
nism used by glucocorticoids to suppress immune responses is by
increasing the expression levels of VDR. Estrogen (Chighizola and
Meroni, 2012) and retinoids (Cassani et al., 2012) also appear to
have strong immunomodulatory effects, but like glucocorticoid
the implication of VDR regulation as a possible mechanism to
modulate immune function has not been investigated. Receptors
for the peptide hormone parathyroid hormone (PTH) was recently
identified on T cells (Geara et al., 2010). This renders PTH-induced
modulation of VDR expression in T cells a possibility as observed
for other cell types (Feldman et al., 2011). Again, this is unexplored
territory even though PTH possesses an immune regulatory abil-
ity (Geara et al., 2010). The most well described hormonal effect
on VDR activity and expression is that of 1,25(OH)2D3 itself,
as 1,25(OH)2D3 directly influences the expression levels of VDR
by homologous regulation. Although varying between different
cell types, 1,25(OH)2D3 in general increases VDR-mRNA produc-
tion (McDonnell et al., 1987), stabilizes VDR-mRNA, and protects
the VDR against degradation (Feldman et al., 2005), altogether
increasing the total amount of the VDR.
Various inflammatory signals have also been shown to induce
upregulation of VDR in immune cells. During an innate immune
response, pathogen-induce activation of toll-like-receptors on
human monocytes and macrophages results in upregulation of
the VDR (Liu et al., 2006). Likewise, antigen-induced activation
of TCR on human naïve T cells induce upregulation of the VDR
(Provvedini et al., 1983; von Essen et al., 2010; Joseph et al., 2012).
Furthermore, T cell cytokines induced during inflammation can
modulate VDR expression (Edfeldt et al., 2010; Spanier et al.,
2012), illustrating that regulation of the VDR level is a common
mechanism used in the defense against pathogens.
INTRACELLULAR SIGNALING PATHWAYS THAT MODULATE VDR
EXPRESSION
Modulation of VDR expression as a result of physical stimuli is
mediated by various intracellular signaling pathways. Although
only a sparse numbers of publications concern this issue, a few
studies agree that activation of the cAMP-dependent protein
kinase A (PKA) pathway leads to an increase in VDR abundance
(Pols et al., 1988; Krishnan and Feldman, 1992; Song, 1996). Both
cellular responses to PTH (Pols et al., 1988) and to prostaglandin
(Smith et al., 1999) activate PKA causing an increase in the VDR
level. In contrast, Feldman and coworkers showed that stimuli that
induce protein kinase C (PKC) activity down-regulate both VDR-
mRNA and VDR protein levels in fibroblastic cells (Krishnan and
Feldman, 1991). Moreover, Reinhardt and Horst (1994) has shown
that the impact of PKC activation on the VDR-mRNA level highly
depends on the particular cellular differentiation state investi-
gated. This suggests that other signaling pathways may cooperate
to determine the final effect on VDR expression. In support of
this idea, a study by Krishnan and Feldman (1992) indicated a
mutual antagonism between the PKA and PKC pathways in regu-
lation of the VDR level, an observation confirmed by others (van
Leeuwen et al., 1992). Furthermore, it has been suggested that
the intracellular calcium level that is known to influence and be
influenced by PKC activity is implicated in PKA induced VDR
upregulation (Figure 1) (van Leeuwen et al., 1990). A new sig-
naling pathway which leads to VDR expression has recently been
described in human naïve T cells. Here, TCR stimulation induces
VDR expression through activation of the p38 mitogen activated
protein kinase by ZAP-70 (Figure 1) (von Essen et al., 2010). In
contrast, Gocek et al. (2007) showed that VDR expression was
controlled by Erk and PI3K signaling in a myeloid leukemia cell
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line where p38 activity appeared irrelevant. This implies that not
only might different intracellular signaling pathways cooperate
to regulate the expression of VDR, but also that the implicated
signaling events differs between different cell types and different
differentiation states of the cells.
TRANSCRIPTIONAL REGULATION OF VDR
Until recently the regulatory responses to hormones at the VDR-
gene promoter were unknown. To clarify this, Zella et al. (2010)
used ChIP–chip analysis to investigate the VDR gene transcription.
These investigations revealed the presence of several enhancers,
including the transcription factor C/EBPβ involved in basal
expression of VDR as well as the transcription factor glucocorti-
coid receptor (GR) which mediates the action of glucocorticoids,
the transcription factor retinoid acid receptor (RAR) mediating
the action of retinoic acid, and the transcription factor CREB
mediating the action of PTH (Zella et al., 2010). In case of VDR
enhancement by 1,25(OH)2D3, Zella et al. (2006, 2010) found
accumulation of VDR-RXR and RNA pol II at the VDR gene
together with an increase in C/EBPβ binding . They also detected
a substantial increase in histon H4 acetylation associated with
enhancer regions across the VDR locus (Zella et al., 2010). An
induction of transcription from promoters is often associated with
an increase in H4 acetylation, and the observations therefore indi-
cated the existence of multiple enhancers in the VDR-gene locus
that may contribute to 1,25(OH)2D3-induced VDR expression.
Transcriptional regulation of the VDR gene therefore includes the
presence and activity of a wide range of enhancers induced by
extracellular signals as well as induction of various epigenetic
changes. In case of inflammatory-induced VDR upregulation,
the regulatory responses at transcriptional level have not been
investigated. As new techniques such as ChIP–chip and ChIP–
seq have emerged, this topic will likely be explored in nearby
future.
POSTTRANSLATIONAL MODIFICATIONS OF VDR
In addition to transcriptional regulation of VDR, several in vitro
studies have suggested that VDR can be post-translationally
modified. Studies by Haussler and coworkers revealed that
1,25(OH)2D3 binding to VDR led to serine phosphorylation at
multiple sites of the receptor. PKC was implicated in phosphoryla-
tion at serine 51, an event that partly inhibitedVDR transcriptional
activity (Hsieh et al., 1991). Although not required for VDR tran-
scriptional activity, casein kinase II (CK II)-induced phosphory-
lation at serine 208 led to an enhancement of VDR transcriptional
activity (Jurutka et al., 1996). As both PKC and CKII activity is
induced in cells in response to various stimuli, it can be proposed
that these posttranslational modifications although probably not
obligatory for VDR function represents a mode to adjust the
activity of VDR according to the specific signals received by the
cell. Disease-induced posttranslational modifications leading to a
dysfunctional VDR has also been documented. In a study by Patel
et al. (1995) plasma toxins from uremic patients was shown to bind
to the patients VDR, thereby disrupting binding of VDR-RXR to
DNA resulting in a diminished VDR response. It so appears that
posttranslational modifications of VDR adjust VDR activity in
both health and disease.
RXR AND OTHER CO-REGULATORS OF VDR
The genomic actions of 1,25(OH)2D3 also highly depends on
the abundance and activity of proteins that interact with VDR.
Binding of VDR to its ligand 1,25(OH)2D3 facilitates association
with RXR and in the absence of RXR, VDR is unable to bind to
most VDRE in vitamin D target genes (Kliewer et al., 1992; For-
man et al., 1995; Chambon, 1996). In addition to RXR binding,
VDR interacts with various co-activators or co-repressors once
bound to the DNA (Nagpal et al., 2005; Pike et al., 2012; Haus-
sler et al., 2013). These co-regulatory complexes are necessary for
the VDR-RXR heterodimer to either induce or suppress gene tran-
scription and include ATPase-containing nucleosomal remodeling
capabilities, enzymes with chromatin histone modifying abili-
ties (e.g., acetyl- or methyl-transferases), and proteins involved
in recruitment of RNA polymerase II (Pike et al., 2012). GRIP1
(Issa et al., 2001), RAC3 (Issa et al., 2001), SRC-1 (Masuyama et al.,
1997a), TIF-1 (vom et al., 1996), ACTR (Chen et al., 1997), pCIP
(Torchia et al., 1997), and Mediator (Oda et al., 2010) are some of
the described co-activator proteins and co-activator complexes to
date. These co-activators all regulate VDR function through co-
assembling with VDR but they modulate VDR activity via distinct
mechanisms. GRIP1 and RAC3 for example regulate VDR activ-
ity by modulating crosstalk between VDR and RXR (Issa et al.,
2001), ACTR encompass histone acetyltransferase capacity and
can recruit other nuclear factors (Chen et al., 1997), and Media-
tor which is a large complex composed of several MED-proteins
activates transcription by direct recruitment of the RNA poly-
merase II transcriptional machinery (Oda et al., 2010). Although
most co-activators facilitate VDR-induced transcriptional activa-
tion by binding to VDR, others are shown to be released from
VDR to enable transcription, e.g., TFIIB (Masuyama et al., 1997b);
illustrating the functional complexity of these co-activator com-
plexes. Only a few co-repressor proteins involved in VDR silencing
of genes have been described. As an example NcoR-1, NcoR-2,
and Hairless can recruit histone deacetylase activity to VDR-target
genes, leading to chromatin compaction and hence gene silencing
(Nagpal et al., 2005). A recent study by Singh et al. (2012) further-
more showed that recruitment of co-repressors inappropriately
can change during disease, causing a deregulation of VDR-target
genes. In addition to transcriptional control of VDR, co-regulator
proteins can modulate VDR abundance by enhancing degradation
of VDR. Certain cellular signaling events have been shown to moti-
vate the physical interaction of VDR-1,25(OH)2D3 with SUG1 of
the proteasome complex, targeting VDR for ubiquitination and
subsequent proteolysis (Masuyama and MacDonald,1998). There-
fore, it is evident that regulation of the expression level of RXR
and other co-regulators are important to modulate the activity
of VDR, and it could be speculated that expression of particular
co-regulators are dictated by the inflammatory environment.
T CELLS MODULATE VDR EXPRESSION IN OTHER IMMUNE CELLS
A recent study by Edfeldt et al. revealed that VDR expression is not
only modulated on a single cell level. Their study showed that VDR
expression of innate immune cells could be regulated by nearby T
cells (Edfeldt et al., 2010). In innate immunity, pathogen-induced
signaling through Toll-like-receptors on human monocytes and
macrophages up-regulate the expression of VDR. This in turn,
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leads to VDR-induced expression of the antimicrobial peptide
cathelicidin resulting in killing of microbes (Liu et al., 2006).
VDR-induced cathelicidin expression by human monocytes was
shown to be adjusted by cytokines produced by T cells. By modu-
lating the level of VDR and the amount of VDR-ligand available by
adjusting the CYP27B1 level, the T cell cytokine IFN-γ increases
cathelicidin expression and IL-4 attenuates cathelicidin expres-
sion (Edfeldt et al., 2010). This example illustrates how inter-
play between innate and adaptive immunity cooperates to mount
an appropriate response to infection through regulation of the
VDR-system.
CONCLUDING REMARKS
This review indicates that VDR expression and activity are impor-
tant for all stages of a T cells life, ranging from development to
differentiation and elicitation of effector functions. In concor-
dance, VDR expression and activity are associated with immunity
against certain infections and with the prevalence of some autoim-
mune diseases. In animal models 1,25(OH)2D3 has been shown
to prevent development of autoimmune diseases. This includes
experimental autoimmune encephalomyelitis (EAE), the animal
model for MS (Mayne et al., 2011). EAE studies performed in
VDR-KO animals (Bouillon et al., 2008) or in animals with a dys-
functional VDR (Mayne et al., 2011) illustrates the requirement of
a functional VDR in 1,25(OH)2D3 mediated EAE-inhibition. Fur-
thermore, a study by Hayes and coworkers showed that VDR-gene
inactivation selectively in the T cells completely eradicated the
ability of 1,25(OH)2D3 to inhibit EAE (Mayne et al., 2011). The
biological relevance of low levels of VDR in development of MS
was confirmed in a microarray analysis performed by Achiron et
al. Here they compared blood mononuclear cells from healthy sub-
jects that later developed MS with healthy subjects that remained
MS-free. One of the early disease markers identified turned out
to be suppressed VDR expression (Achiron et al., 2010). These
observations may not only reflect a change in conventional T cells
(e.g., development of more memory T cells that are predisposed
to develop into Th1 and Th17 cells as observed in VDR-KO mice
(Bruce et al., 2011) but also a reduced development of iNKT cells
(as observed in VDR-KO mice, Yu and Cantorna, 2008; Ooi et al.,
2012). iNKT cells are negative regulators of EAE (Matsuda et al.,
2008) and furthermore, fewer iNKT cells can be found in the blood
of MS patients (Araki et al., 2003). Along this line Araki et al. (2003)
showed that an increase in iNKT cell number is associated with
remission from symptoms in MS patients. Altogether, these obser-
vations emphasize a role for VDR expression in development and
progression of autoimmunity.
Most experiments investigating susceptibility to a given
autoimmune disease is, however, based on animal models. The
question therefore remains whether these animal models which
are executed in a pathogen free environment reflect the real
life situation where humans continuously are bombarded with
a variety of pathogens. It is slowly becoming apparent that the
microbial environment has a greater influence on development
of autoimmune diseases than previously anticipated. For exam-
ple, certain microbes have been shown to slow innate immune
defenses by dysregulating the VDR. One mechanism used by
the innate immune system to clear a pathogen is VDR-induced
production of the antimicrobial peptide cathelicidin which pos-
sesses antiviral, antibacterial, and antifungal activity. Therefore,
any microbe capable of dysregulating expression of the VDR
would enhance its chance for survival (Waterhouse et al., 2009;
Proal et al., 2013). Klein and coworkers illustrated in vitro that
Epstein-Barr virus (EBV) were able to effectively down-regulate
expression of VDR in B cells (Yenamandra et al., 2009), Modlin
and coworkers that Mycobacterium leprae inhibits VDR activ-
ity through down-regulation of CYP27B1 in monocytes (Liu
et al., 2012), Wang and coworkers that Mycobacterium tubercu-
losis down-regulate expression of VDR in macrophages (Xu et al.,
2003), and McElvaney and coworkers that the fungus Aspergillus
fumigates secretes a toxin capable of down-regulating VDR in
macrophages (Coughlan et al., 2012). This allows pathogens to
accumulate in tissue and blood and the weakened innate defense
further causes susceptibility to additional infections. As more
pathogens are incorporated into this microbiome, people start to
show symptoms characteristic of inflammatory and autoimmune
diseases. Accumulating evidence now supports the observation
that a number of autoimmune diseases can be reversed by restor-
ing VDR function (using the VDR agonist olmesartan) along with
antibiotics. This includes rheumatoid arthritis, systemic lupus
erythematosis, sarcoidosis, scleroderma, psoriasis, Sjogren’s syn-
drome, autoimmune thyroid disease, and type I and II diabetes
mellitus (Waterhouse et al., 2009; Proal et al., 2013). Knowledge
of the regulation of VDR abundance and activity in immune cells
potentially is of great therapeutic importance, and therapeutic
enhancement of VDR should therefore be considered in the clinic
today.
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